Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020


December 1, 2010
217 Pages - SKU: GBDT6007636
License type:
Table of Contents Search inside this report Related Reports
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Disease Overview
2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Prostate Specific Antigen Test
2.5.3 Transrectal Ultrasound
2.5.4 Prostate Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.8 Treatment Guidelines
3 Market Characterization
3.1 Japan
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.5 Future Impact
3.1.6 Drug Sales
3.1.7 Pricing & Reimbursements
4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles
4.3.1 Taxotere (docetaxel)
4.3.2 Casodex (Bicalutamide)
4.3.3 Zoladex (Goserelin)
4.3.4 Lupron (Leuprolide acetate)
4.3.5 Firmagon (degarelix)
4.3.6 Novantrone (Mitoxantrone hydrochloride)
4.3.7 Emcyt (estramustine)
4.3.8 Trelstar (triptorelin)
4.3.9 Eulexin
4.3.10 Delestrogen
4.3.11 Gynodiol
4.3.12 Estrace tablet
4.3.13 Tace
4.3.14 Nilandrone
4.3.15 Premarin
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol
5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development
5.6 Partners in Research and Development
5.6.1 Licensing Agreements by Phase of Development
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
5.7 Most Promising Drugs’ Profiles
5.7.1 Provenge (sipuleucel-T)
5.7.2 Jevtana (cabazitaxel)
5.7.3 Aflibercept (VEGF Trap)
5.7.4 Ipilimumab
5.7.5 Abiraterone Acetate (CB7630)
5.7.6 Zibotentan (ZD4054)
5.7.7 Sprycel (dasatinib)
5.7.8 MDV3100
5.8 Prostate Cancer Pipeline - Pre-clinical Phase
5.9 Prostate Cancer Pipeline - Phase I
5.10 Prostate Cancer Pipeline - Phase II
5.11 Prostate Cancer Pipeline - Phase III
5.12 Key Takeaway
6 Unmet Need and Target Product Profile
6.1 Unmet Need
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy
6.2 Opportunity for Target Product
6.3 Target Product Profile
6.3.1 Ideal Characteristics
6.3.2 Target Product Description
6.4 Key Takeaway
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway
8 Company Profiles
8.1 Sanofi-aventis
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.4 Oncology Focus
8.2 Pfizer Inc.
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.4 Oncology Focus
8.3 AstraZeneca
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.4 Oncology Focus
8.4 Bristol-Myers Squibb
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 SWOT Analysis
8.4.4 Oncology Focus
8.5 Medivation
8.5.1 Business Description
8.5.2 SWOT Analysis
8.5.3 Oncology Focus
8.6 Takeda Pharmaceuticals
8.6.1 Business Description
8.6.2 SWOT Analysis
8.7 Dendreon Corporation
8.7.1 Business Description
8.7.2 SWOT Analysis
8.8 Johnson and Johnson
8.8.1 Business Description
8.8.2 SWOT Analysis
8.8.3 Oncology Focus
8.9 Auron Healthcare GmbH
8.9.1 Business Description
8.10 Oncogenex Pharmaceuticals, Inc.
8.10.1 Business Description
8.11 Agennix AG
8.11.1 Business Description
8.12 GTx, Inc.
8.12.1 Business Description
8.13 GlaxoSmithKline plc.
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.4 Oncology Focus
9 M&A Analysis
9.1 Key Highlights
9.2 Key Deals’ Analysis
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
9.2.3 Tolmar Holding Acquires QLT USA from QLT
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co.
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax
9.2.8 GPC Biotech Merges with Agennix
9.2.9 Eli Lilly Acquires ImClone
9.2.10 BBM Holdings Acquires YM BioSciences
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals
9.3 M&A Deals by Geography
9.4 M&A Deals by Deal Size
10 Expert Opinion
10.1 Japan
11 Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Forecasting
11.3.4 Primary Research
11.3.5 Expert Panel validation
11.3.6 Contact Us
11.3.7 Disclaimer
11.3.8 Sources
1.1 List of Tables
Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010
Table 3: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009
Table 4: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009
Table 5: Prostate Cancer Therapeutics Market, Japan, Patient Volume (’000s), 2001-2009
Table 6: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (’000s), 2001-2009
Table 7: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020
Table 8: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020
Table 9: Prostate Cancer Therapeutics Market, Japan, Patient Volume (’000s), 2009-2020
Table 10: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (’000s), 2009-2020
Table 11: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010
Table 12: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020
Table 13: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010
Table 14: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020
Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010
Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010
Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010
Table 18: Prostate Cancer, Japan, Benchmarking Major Marketed Products, 2010
Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010
Table 20: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products
Table 21: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010
Table 22: Prostate Cancer, Global, Licensing Agreements, 2009-2010
Table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010
Table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010
Table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010
Table 26: Prostate Cancer, Global, Phase I Pipeline, August 2010
Table 27: Prostate Cancer, Global, Phase II Pipeline, August 2010
Table 28: Prostate Cancer, Global, Phase III Pipeline, August 2010
Table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
Table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
Table 31: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010
Table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010
Table 33: Prostate Cancer, Global, M&A Deals by Geography, 2010
1.2 List of Figures
Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
Figure 2: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009
Figure 3: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009
Figure 4: Prostate Cancer Therapeutics Market, Japan, Patient Volume (’000s), 2001-2009
Figure 5: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (’000s), 2001-2009
Figure 6: Prostate Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2009
Figure 7: Prostate Cancer Therapeutics Market, Japan, Historical Events Impact on the Market, 2010
Figure 8: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2009-2020
Figure 9: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009-2020
Figure 10: Prostate Cancer Therapeutics Market, Japan, Patient Volume (’000s), 2009-2020
Figure 11: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (’000s), 2009-2020
Figure 12: Prostate Cancer Therapeutics Market, Japan, Future Events Expected to Impact the Market, 2010
Figure 13: Prostate Cancer Therapeutics Market, Japan, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 14: Prostate Cancer Therapeutics Market, Japan, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010
Figure 17: Prostate Cancer Therapeutics Market, Japan, Sales Forecast by Therapies, 2001-2020
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010
Figure 20: Prostate Cancer, Japan, Taxotere, Sales ($m), 2004-2020
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010
Figure 23: Prostate Cancer, Japan, Casodex, Sales ($m), 1999-2020
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure
Figure 25: Prostate Cancer, Japan, Zoladex, Sales Forecast ($m), 2002-2020
Figure 26: Prostate Cancer, Global, Lupron, Chemical Structure
Figure 27: Prostate Cancer, Japan, Leuprolide (Lupron), Sales Forecast ($m), 2001-2020
Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure
Figure 29: Prostate Cancer, Japan, Firmagon, Sales Forecast ($m), 2009-2020
Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure
Figure 31: Prostate Cancer, Japan, Mitoxantrone, Sales Forecast ($m), 2001-2020
Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure
Figure 33: Prostate Cancer, Japan, Estramustine, Sales Forecast ($m), 2001-2020
Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure
Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure
Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure
Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure
Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure
Figure 39: Prostate Cancer, Global, Tace, Chemical Structure
Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure
Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure
Figure 42: Prostate Cancer, Japan, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020
Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010
Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010
Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010
Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010
Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010
Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010
Figure 50: Prostate Cancer, Japan, Provenge, Sales Forecast ($m), 2016-2020
Figure 51: Prostate Cancer, Japan, Jevtana, Sales Forecast ($m), 2013-2020
Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure
Figure 53: Prostate Cancer, Japan, Aflibercept, Sales Forecast ($m), 2016-2020
Figure 54: Prostate Cancer, Japan, Ipilimumab , Sales Forecast ($m), 2014-2020
Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure
Figure 56: Prostate Cancer, Japan, Abiraterone, Sales Forecast ($m), 2015-2020
Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure
Figure 58: Prostate Cancer, Japan, Zibotentan , Sales Forecast ($m), 2015-2020
Figure 59: Prostate Cancer, Japan, Sprycel , Sales Forecast ($m), 2013-2020
Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure
Figure 61: Prostate Cancer, Japan, MDV3100 , Sales Forecast ($m), 2015-2020
Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010
Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010
Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010
Figure 65: Prostate Cancer, Japan, Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 66: Prostate Cancer, Japan, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 67: Prostate Cancer, Japan, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market
Figure 69: Prostate Cancer, Japan, Implications for Future Market Competition, 2010
Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010
Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010
Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010
Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010
Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010
Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010
Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010
Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010
Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010
Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010
Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010
Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010
Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010
Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010
Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010
Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010
Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010
Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010
Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010
Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010
Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010
Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010
Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010
Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010
Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010
Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010
Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010
Figure 97: Prostate Cancer, Japan, Key Data Inputs from KOL Interviews, July 2010
Figure 98: GlobalData Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Men's Health Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!